Cartesian Therapeutics, Inc. Common Stock (RNAC) Stock Price

RNACStock

$9.60−6.61%52W

Market Cap$290.45M

P/E—

PEG Ratio—

Div yield—

Beta0.66

RNAC Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)15.22%

Price vs S&P 500 (4W)20.44%

VGM Score26.15

Book Value / Share (Quarterly)$0.03

P/TBV (Annual)2.30x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-70.66%

Cash Flow / Share (Quarterly)$-2.71

Price vs S&P 500 (YTD)20.33%

Net Profit Margin (TTM)-8550.65%

EPS (TTM)$-5.80

10-Day Avg Trading Volume0.14M

EPS Excl Extra (TTM)$-5.80

Revenue Growth (5Y)-29.96%

EPS (Annual)$-5.02

ROI (Annual)29.46%

Net Profit Margin (5Y Avg)-1140.15%

Cash / Share (Quarterly)$4.16

Revenue Growth QoQ (YoY)-92.91%

ROA (Last FY)-43.96%

Revenue Growth TTM (YoY)-94.93%

EBITD / Share (TTM)$-5.53

ROE (5Y Avg)-185.49%

Operating Margin (TTM)-8338.87%

Cash Flow / Share (Annual)$-3.05

P/B Ratio356.26x

P/B Ratio (Quarterly)512.19x

Net Income / Employee (Annual)$-1,737,400

EV / Revenue (TTM)84.10x

Net Interest Coverage (TTM)-0.62x

ROA (TTM)-45.09%

EPS Incl Extra (Annual)$-5.02

Current Ratio (Annual)8.65x

Quick Ratio (Quarterly)7.46x

3-Month Avg Trading Volume0.23M

52-Week Price Return-6.61%

EV / Free Cash Flow (Annual)3.02x

Revenue / Employee (TTM)$23,700

Tangible BV / Share (Quarterly)$0.39

P/S Ratio (Annual)95.79x

Asset Turnover (Annual)0.01x

52-Week High$11.00

Operating Margin (5Y Avg)-1112.90%

EPS Excl Extra (Annual)$-5.02

CapEx CAGR (5Y)46.26%

Tangible BV CAGR (5Y)12.61%

26-Week Price Return27.15%

Quick Ratio (Annual)8.45x

13-Week Price Return33.15%

Total Debt / Equity (Annual)0.28x

Current Ratio (Quarterly)7.65x

Enterprise Value$149.27M

Revenue / Share Growth (5Y)-53.44%

Asset Turnover (TTM)0.01x

Book Value / Share Growth (5Y)-23.36%

Revenue / Employee (Annual)$37,300

Pretax Margin (Annual)-4987.31%

Cash / Share (Annual)$4.81

3-Month Return Std Dev87.70%

Net Income / Employee (TTM)$-2,023,700

ROE (Last FY)37.71%

Net Interest Coverage (Annual)-0.64x

EPS Basic Excl Extra (Annual)$-5.02

P/FCF (TTM)35.76x

Receivables Turnover (TTM)1.75x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-5.80

Receivables Turnover (Annual)2.82x

ROI (TTM)-3215.82%

P/S Ratio (TTM)150.94x

Pretax Margin (5Y Avg)-1216.71%

Revenue / Share (Annual)$0.11

Tangible BV / Share (Annual)$0.61

Price vs S&P 500 (52W)-25.17%

Year-to-Date Return33.15%

5-Day Price Return-4.57%

EPS Normalized (Annual)$-5.02

ROA (5Y Avg)-25.70%

Net Profit Margin (Annual)-4658.63%

Month-to-Date Return23.08%

Cash Flow / Share (TTM)$-0.23

EBITD / Share (Annual)$-5.41

Operating Margin (Annual)-5127.10%

LT Debt / Equity (Annual)0.19x

ROI (5Y Avg)-74.06%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-5.80

P/TBV (Quarterly)3.57x

P/B Ratio (Annual)2.17x

Pretax Margin (TTM)-9068.56%

Book Value / Share (Annual)$0.61

Price vs S&P 500 (13W)31.19%

Beta0.66x

P/FCF (Annual)7.86x

Revenue / Share (TTM)$0.07

ROE (TTM)-3215.82%

52-Week Low$5.60

vGradeF

gGradeF

mGradeB

vgmGradeD

RNAC Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 6, 2026	-$0.65	-$0.96	-48.27%(-$0.31)
Q1 2026	Apr 30, 2026	-$0.70	-$0.95	-35.51%(-$0.25)
Q4 2025	Mar 9, 2026	-$0.79	-$2.71	-242.59%(-$1.92)
Q3 2025	Nov 6, 2025	-$0.63	-$0.73	-16.00%(-$0.10)
Q2 2025	Aug 7, 2025	-$0.65	-$0.77	-18.83%(-$0.12)

RNAC Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.20

4.29

Industry Peers — Pharmaceuticals(570)

Symbol	Value Score	Growth Score	Momentum Score	Price
RNACCartesian Therapeutics, Inc. Common Stock	F	F	B	$9.60
LLYEli Lilly & Co.	D	B	C	$1174.61
JNJJohnson & Johnson	D	C	B	$268.04
ABBVABBVIE INC.	D	C	B	$255.48
MRKMerck & Co., Inc.	D	C	B	$148.35
NVSNovartis AG	C	C	C	$153.81
AZNAstraZeneca PLC	C	B	C	$162.70
NVONovo-Nordisk A/S	B	C	C	$45.61
ABTAbbott Laboratories	C	C	C	$112.47
PFEPfizer Inc.	C	D	B	$27.96
VRTXVertex Pharmaceuticals Inc	D	C	B	$541.69
BMYBristol-Myers Squibb Co.	B	B	B	$66.58
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$44.82
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$50.82
REGNRegeneron Pharmaceuticals Inc	C	C	B	$794.19
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	B	$18.03
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$36.44
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	$366.73
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$60.85
ZTSZOETIS INC.	C	C	D	$77.34
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$237.10
INSMInsmed, Inc.	F	A	C	$118.54
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$34.71
UTHRUnited Therapeutics Corp	C	C	B	$515.46
GMABGenmab A/S ADS	C	C	B	$33.23
VTRSViatris Inc. Common Stock	B	C	B	$16.34
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$247.91
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$244.54
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$76.60
BMRNBioMarin Pharmaceuticals Inc	C	C	B	$64.67
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	B	$533.76
CORTCorcept Therapeutics Inc.	F	C	B	$113.88
ELANElanco Animal Health Incorporated Common Stock	C	B	C	$24.11
ARWRArrowhead Research Corporation	D	A	B	$84.91
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.73
AXSMAxsome Therapeutics, Inc	D	B	C	$199.02
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.18
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$61.05
CYTKCytokinetics Inc.	F	D	C	$72.09
ABVXAbivax SA American Depositary Shares	—	—	C	$113.35
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$344.75
PTGXProtagonist Therapeutics, Inc	F	B	B	$144.33
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.84
TGTXTG Therapeutics, Inc.	D	B	B	$53.93
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	$90.36
ALKSAlkermes Inc. plc	D	C	B	$47.41
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$107.17
ERASErasca, Inc. Common Stock	—	—	A	$18.03
TVTXTravere Therapeutics, Inc. Common Stock	F	B	A	$65.67
BLTEBelite Bio, Inc American Depositary Shares	—	—	C	$151.72

About Cartesian Therapeutics, Inc. Common Stock

Cartesian Therapeutics is a clinical-stage biopharmaceutical company developing mRNA-based therapies to induce immune tolerance. The company's ImmTOR platform uses proprietary manufacturing and cellular engineering technology to mitigate unwanted immune responses, particularly in autoimmune and transplant-related conditions. This approach represents a novel mechanism for treating conditions where immune suppression needs to be targeted rather than systemic.